<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="190143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617942</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG-BR-211B</org_study_id>
    <nct_id>NCT00617942</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer</brief_title>
  <official_title>BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Sikov</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable
      and unresectable HER2+ (stage IIa-IIIb) breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our goal is to develop an induction chemotherapy regimen that will have a pCR rate above 50%
      in HER2+ patients without exposing patients to the toxicity of an anthracycline-based
      regimen. A minimum of 60 evaluable patients will be accrued to the study. We are assuming an
      observed pCR (or near pCR) rate of 70%. Assuming no more than 10% of patients will be
      inevaluable for the primary endpoint (pCR), we will have at least 54 evaluable patients.
      With this number, we will have 90% power, with a 1-sided alpha error of 0.05, to demonstrate
      a pCR rate exceeding 50% for our novel regimen.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the clinical and pathologic response rates, particularly the pCR/near pCR rate, observed following treatment with q3week carboplatin, weekly Abraxane and weekly trastuzumab in resectable and unresectable LABC;</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess toxicities of regimen during treatment, including grade &gt;2 neurotoxicity the incidence of subclinical and clinical cardiac toxicity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Carboplatin, Abraxane, Trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 6</description>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Abraxane (nab-paclitaxel), Herceptin (trastuzumab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Abraxane 100 mg/m2</description>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Abraxane (nab-paclitaxel)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>trastuzumab 2 mg/kg</description>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Herceptin (trastuzumab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented adenocarcinoma of the breast

          -  ANC &gt; 1000 cells

          -  Female; age &gt; 18; Zubrod PS 0-1

          -  Platelets &gt; 100,000

          -  Stage IIA-IIIB disease

          -  Total bilirubin &lt; or = ULN

          -  No evidence of metastatic disease Not pregnant or lactating

          -  No prior systemic therapy for this breast cancer

          -  Serum Creatinine &lt; 1.5 mg/dl or Creat Cl &gt; 30 ml/min

          -  Serum ALT &lt; 2.5 x ULN

          -  ER, PR and HER2 status required

          -  LVEF (MUGA/echo)WNL

          -  No baseline &gt; 2 neuropathy

          -  Hemoglobin &gt; 9.0 gm/dl

          -  HER2+, defined by IHC 3+ or FISH ratio &gt; 2.0
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Sikov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Smilow Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Williams Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island and The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 15, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>William Sikov</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
